Endonovo Therapeutics (OTCQB: ENDV), an innovative
biotechnology company, is poised to profit as the wearable medical devices
market is forecasted to rapidly increase over the coming years. An article
discussing the company reads, “The global wearable medical devices market is
anticipated to grow to $66.8 billion by 2026, a Grandview Research report
published in April 2019 suggests (http://ibn.fm/AzXnV). The market is forecast to expand at a
CAGR of 26.1% over the period, with several factors contributing to the growth.
. . . Increased health awareness and a better understanding of the need for
constant monitoring will both help the market expand. In addition, the Western
world’s population is aging, and the prevalence of chronic medical conditions
is increasing. Wearable devices can be used to monitor various important health
parameters, to prompt a more active lifestyle and even to address an array of
treatable conditions.”
To view the full article, visit http://ibn.fm/xrjBL
About Endonovo Therapeutics Inc.
Endonovo Therapeutics is a commercial-stage developer of
noninvasive wearable electroceuticals(TM) therapeutic devices. The company’s
current portfolio of commercial and clinical-stage wearable electroceuticals
therapeutic devices addresses wound healing, pain, postsurgical pain and edema,
cardiovascular disease, chronic kidney disease and central nervous system
(“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions,
postconcussion syndrome and multiple sclerosis. The company’s noninvasive
electroceutical therapeutic device, SofPulse(R), using pulsed short-wave
radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the
palliative treatment of soft-tissue injuries and postoperative pain and edema,
and has CMS national coverage for the treatment of chronic wounds. The
company’s current portfolio of preclinical-stage electroceuticals therapeutic
devices address chronic kidney disease, liver disease nonalcoholic
steatohepatitis (“NASH”), cardiovascular and peripheral artery disease (“PAD”),
and ischemic stroke. The company’s noninvasive, wearable electroceuticals
therapeutic devices work by restoring key electrochemical processes that
initiate anti-inflammatory and growth-factor cascades necessary for healing to
occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates
relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment